Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease.
P.I.: Karen S. Servilla, MD, FACP
Synopsis – Testing the new medication, vadadustat to determine if it is an effective treatment for anemia (low red blood cell count) in patients with chronic (long-term)kidney disease.
Share This Story